Evidence map›Paper›PMID 39660524›Full record

ReviewPharmaceutical nanotechnology2026

Emerging Trends in Transdermal Drug Delivery: Nanoparticle Formulations and Technologies for Enhanced Skin Penetration and Drug Efficiency.

Kiran Dudhat

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmaceutical nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Kiran DudhatSchool of Pharmacy, RK University, Kasturbadham, Rajkot, Gujarat, 360020, India.ORCID 0000-0001-6621-1319

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transdermal drug delivery systems (TDDS) have emerged as a popular non-invasive approach for treating skin-related disorders, offering quick and reliable drug delivery into the skin, thereby accelerating therapeutic efficacy. In India, there is a growing interest in TDDS due to its perceived safety and effectiveness. Researchers are actively developing new formulations and technologies to enhance drug delivery efficiency and reduce side effects. Recent trends indicate a focus on overcoming challenges such as low permeability and stability issues through innovative nanoparticle-based delivery systems. Nanotechnology has revolutionized transdermal drug delivery by offering precise control over nanoparticle properties, enabling enhanced skin permeation and targeted delivery. Various nanoparticle formulations, including polymeric nanoparticles, liposomes, nanotubes, solid lipid nanoparticles, and nanoemulsions, have shown promise in improving drug solubility, bioavailability, and sustained release. Additionally, microneedles have emerged as a successful transdermal delivery method, offering advantages over traditional creams and patches. Metallic nanocarriers and nanoemulsions are also being explored for their potential in targeted drug delivery and enhanced skin penetration. Despite these advancements, challenges such as toxicity and biocompatibility need to be addressed for widespread clinical translation. Overall, the growing interest in transdermal drug delivery systems in India reflects the potential for improved therapeutic outcomes and patient convenience through innovative nanoparticle- based formulations and technologies.

Indexed as

Drug Delivery SystemsNanoparticlesSkinSkin AbsorptionAdministration, CutaneousAnimalsHumansMicroneedle Drug DeliveryPharmaceutical PreparationsPharmaceutical Preparationsmetallic nanocarriersmicroneedlesnanoemulsions.nanoparticlesnanotechnologyTransdermal drug delivery systems

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.